Tiziana Life Sciences Ltd
TLSA
$1.18
$0.054.43%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
6/25/2026
-
Proactive Investors - UK
6/25/2026
-
Proactive Investors - UK
6/25/2026
-
TipRanks
6/25/2026
-
Globe Newswire
6/15/2026
-
Seeking Alpha - Healthcare
5/22/2026
-
Proactive Investors - UK
5/21/2026
-
Stocktwits News Feed
5/21/2026
-
Proactive Investors - UK
5/19/2026
-
Proactive Investors - UK
5/19/2026
-
Proactive Investors - UK
5/19/2026
-
Proactive Investors - UK
5/19/2026
-
TipRanks Financial Blog
5/19/2026
-
Globe Newswire
5/14/2026
-
Proactive Investors - UK
5/14/2026
-
Proactive Investors - UK
5/14/2026
-
TipRanks Financial Blog
5/14/2026
-
Globe Newswire
4/30/2026
-
TipRanks Financial Blog
4/18/2026
-
MarketBeat
4/16/2026
-
Proactive Investors - UK
4/16/2026
-
Proactive Investors - UK
4/14/2026
-
Proactive Investors - UK
4/14/2026
-
Proactive Investors - UK
4/14/2026
-
Globe Newswire
4/2/2026
-
MarketBeat
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Friday, May 1, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Beginning of October (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
44 20 7495 2379
Address
14/15 Conduit Street
London, W1S 2XJ
London, W1S 2XJ
Country
Year Founded
--
Business Description
Sector
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and...
more